GSK Expands Share Buyback Program with Recent Purchase

The latest update is out from GlaxoSmithKline ( (GB:GSK) ).

GSK plc announced the purchase of 180,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired at a volume-weighted average price of 1,766.33 pence, will be held as treasury shares. This transaction, facilitated through BNP Paribas SA, contributes to the total of 10,138,000 shares repurchased since the program’s announcement on 30 September 2025. Following this purchase, GSK holds 235,602,844 shares in treasury, with a total of 4,079,829,083 shares in issue, excluding treasury shares. This buyback effort is part of GSK’s strategy to manage its capital structure and return value to shareholders.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s strong technical indicators and positive earnings call sentiment are the most significant factors driving the high score. The company’s solid financial performance, despite some concerns about cash flow and debt reliance, supports a favorable outlook. Valuation metrics further enhance its attractiveness, making GSK a compelling investment in the drug manufacturing sector.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GlaxoSmithKline (GSK) is a leading global healthcare company that operates in the pharmaceutical industry. The company primarily focuses on the development and manufacturing of vaccines, specialty medicines, and consumer healthcare products.

Average Trading Volume: 8,546,353

Technical Sentiment Signal: Buy

Current Market Cap: £72.21B

For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.